Case study:
Indication prioritization
Indication prioritization and sequencing for an oncology asset with expected activity on multiple tumor types
Identification of indications with highest unmet need, lowest payer data requirements and highest willingness to pay helped to prioritize and sequence indications.
Challenge
Novel oncology agent expected to show activity in several tumor types
Significant differences across indications in competitive landscape and unmet need
Need to prioritize indications and determine optimal sequence given limited research budget and differences in willingness to pay
Actions
Secondary research on previous payer decisions and HTA appraisals in oncology
Primary research with payers and KOLs in order to determine for each target indication:
- Unmet need
- Data requirements (endpoints and quantity of effect) to guarantee reimbursement
- Willingness to pay
Result
Significant differences across indications identified: e.g. moderate PFS improvement sufficient in high unmet need indication opposed to larger OS improvement required in indication with many competitors
Clear and actionable recommendations on lead indication and sequence in order to optimize pricing & reimbursement
